The largest trial of nicotinamide riboside was published validating the efficacy and safety of Chroma Dex’s proprietary form of NR, Niagen. This is first clinical trial study measuring both kinetics and dose-dependent effects of chronic Niagen supplementation.
132 healthy overweight adults as subjects were enrolled. The study conducted was randomized, double-blind, placebo-controlled and parallel arm trial. As per the data, it demonstrates the way of supplementation with three different daily doses of Niagen (100mg, 300mg, 1000mg) initially elevated and then sustained increase in NAD levels in blood over the span of an 8-week period.
The observations of this study support directly the efficacy of NAD-boosting Tru Niagen, recommending 300 mg as daily serving in the United States. On average, study subjects consuming 300 mg/day experienced a statistically significant 51% increase in whole blood NAD+ within two weeks. This elevation was maintained throughout the remainder of the eight-week study.
All doses were tested and they showed well-tolerance with no attributable adverse events. By the end of the eight-week trial, observation showed no change in LDL cholesterol levels or blood levels of homocysteine. These results further distinguish Niagen from other NAD-boosting supplements and support Niagen upper limit versus other B3 vitamins.
Clinical Research Newsletter
Mr Vinod Arora, Principal Advisor, IGMPI
Placement testimonials: Our alumni are working with Fortune 500 and global Pharmaceutical, Food and healthcare giants like